MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova announced it has achieved the target enrollment of 200 patients in the SEANOBI-ALS study, an NIH-funded expanded access program evaluating MN-166 (ibudilast) in ALS patients. The program is designed to provide access to individuals not eligible for randomized trials, with final patient follow-ups projected to conclude in early 2027 to support data analysis and scientific publications.
Key figures
- Enrollment target
- 200
- Follow up completion
- early 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.